Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Oklo Inc (OKLO) vs Viatris Inc (VTRS) Price & Performance

Viatris IncTrade

Price performance (Past 24H)

Key statistics

Oklo Inc vs Viatris Inc — how do they compare? Oklo Inc trades at $42.52 (market cap $8.06B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 2.4× Oklo Inc's market cap, and Viatris Inc pays a 2.89% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.

OKLOVTRS
Market Cap
$8.06B$19.09B
Sector
TechnologyHealth
52-Week High
$174.14$17.86
52-Week Low
$36.84$9.49
Enterprise Value
$5.60B$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Oklo Inc

OKLO trades at $43.31, up 4.94% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces fundamental challenges, including negative net income margins of -12,625.54% and significant cash burn from operations. Recent news highlights progress in small modular reactor projects but also delays, such as a 14-month setback for its Ohio project noted by Zacks Investment Research on September 1, 2026.

Wall Street maintains a bullish outlook with a $71.58 consensus price target and 71.43% buy ratings, driven by long-term potential in nuclear energy for AI power demand. Key risks include lack of profitability, project execution delays, and high valuation multiples amid substantial cash outflows, requiring careful risk assessment by investors.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Oklo Inc

Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.

Read more on OKLO

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS